Leica Biosystems, a global leader in cancer diagnostics and digital pathology, has announced a strategic partnership with L7 Informatics, a pioneer in data unification and workflow orchestration for the life sciences. The collaboration aims to advance the future of pathology informatics by integrating L7|ESP (Enterprise Science Platform) into Leica Biosystems’ next-generation, AI-ready solutions spanning the entire pathology laboratory workflow.
Today’s pathology departments face significant strain. Increasing diagnostic volumes, persistent staffing shortages, and fragmented data systems continue to slow processes and delay critical diagnoses. One of the biggest obstacles is the lack of seamless data flow across instruments and systems, which makes it difficult to generate timely, actionable insights.
The partnership directly addresses these challenges by bringing together Leica Biosystems’ advanced pathology instrumentation with L7|ESP’s modern digital infrastructure. This integration will help automate, coordinate, and unify processes across the complete pathology workflow. The result: improved reproducibility, enhanced operational efficiency, reduced time-to-diagnosis, and stronger support for AI-driven decision-making—capabilities that are becoming indispensable as labs strive for faster and more precise cancer diagnostics.
“Our partnership with Leica Biosystems represents the next stage of digital transformation in diagnostics,” said Mark L. Spencer, president and CEO of L7 Informatics. “Together, we’re combining Leica Biosystems’ leadership in pathology with L7’s expertise in unified data and workflow orchestration to build the infrastructure required for the next decade of AI-enabled discovery and diagnosis. Our collaboration with Leica Biosystems underscores a shared commitment to our customers and partners, and to patients.”
“This work builds on our more than 150-year heritage of pathology innovation and expertise across the laboratory workflow,” said William Day, vice president and general manager, advanced staining instruments at Leica Biosystems. “L7|ESP provides the foundation for our next-generation data connectivity and automation solutions, enabling unified data and automated, streamlined workflows across pathology labs. This powerful advancement empowers laboratory professionals to focus on the work—rather than the workflow—so they can deliver faster, more reliable results with greater ease and efficiency.”
As part of the collaboration, Leica Biosystems is now incorporating L7|ESP into its workflow development efforts, with commercial product availability targeted for early 2026.
Leica Biosystems continues to be a global leader in anatomic and digital pathology, offering a comprehensive range of solutions covering every step from sample preparation and staining to imaging and reporting. L7 Informatics, founded in 2012 and headquartered in Austin, Texas, is transforming digital operations in the life sciences through L7|ESP, a platform designed to unify data, automate workflows, and support AI-driven operations across R&D, manufacturing, diagnostics, and clinical environments.
Also Read